Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
CYP3A5 and breast cancer are reported together in 2 articles.
Gene
CYP3A5
- HGNC
- HGNC:2638
28articles
28mentions
3variants with confirmed gene link
Most co-reported phenotypes (articles)
stroke 3autism spectrum disorder 2breast cancer 2familial hypercholesterolemia 2leukemia 2obesity 2Alstrom syndrome 1Down syndrome 1
Reported variants (articles · ClinVar status)
Phenotype
Breast cancer
1,211articles
1,211mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
2 records shown · first 60Human genome meeting 2016 : Houston, TX, USA. 28 February - 2 March 2016.
PMID 27294413 | PMCID PMC4896275 | DOI 10.1186/s40246-016-0063-5 · Human genomics · 2016 · 28 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CYP3A5 | “Ibrahim P46 Genetic divergence of CYP3A5*3 pharmacogenomic marker for native and admixed Mexican populations J.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Xiong, David A Bennett O11 A microRNA signature identifies subtypes of triple-negative breast cancer and reveals MIR-342-3P as regulator of a lactate metabolic pathway A.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | SCN5A | “Karnani, GUSTO study group O4 High-throughput identification of specific qt interval modulating enhancers at the SCN5A locus A.” | 0.98 | hgnc_dict_v1 |
| gene | MYC | “Carter O17 Recurrent somatic mutation in the MYC associated factor X in brain tumors H.” | 0.98 | hgnc_dict_v1 |
Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.
PMID 22012257 | DOI 10.1007/s00228-011-1134-0 · European journal of clinical pharmacology · 2012 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | CYP3A5 | “Genotyping of cytochrome P450 enzymes CYP2B6, CYP2C9, CYP2C19, CYP3A5, aldehyde dehydrogenase (ALDH3A1), and glutathione S-transferase (GSTA1) was done either through RFLP or pyrosequencing.” | 0.98 | hgnc_dict_v1 |
| phenotype | breast cancer | “Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CYP2B6 | “Genotyping of cytochrome P450 enzymes CYP2B6, CYP2C9, CYP2C19, CYP3A5, aldehyde dehydrogenase (ALDH3A1), and glutathione S-transferase (GSTA1) was done either through RFLP or pyrosequencing.” | 0.98 | hgnc_dict_v1 |
| gene | CYP2C9 | “Genotyping of cytochrome P450 enzymes CYP2B6, CYP2C9, CYP2C19, CYP3A5, aldehyde dehydrogenase (ALDH3A1), and glutathione S-transferase (GSTA1) was done either through RFLP or pyrosequencing.” | 0.98 | hgnc_dict_v1 |